On October 17, 2022 Ferring Pharmaceuticals and Blackstone Life Sciences reported that they have reached an agreement to restructure their 2019 collaboration in nadofaragene firadonavec, an investigational novel gene therapy in late-stage development for patients with high-grade, Bacillus Calmette-Guerin unresponsive, non-muscle invasive bladder cancer (Press release, Ferring, OCT 17, 2022, View Source [SID1234622068]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of this restructuring, Ferring will now assume full and sole control of FerGene and nadofaragene firadonavec. The restructured agreement allows for a return on capital already invested by Blackstone, and also provides Blackstone with the option to make a passive financial investment in nadofaragene firadonavec upon achievement of a specified regulatory event in exchange for a royalty interest.

Ferring is committed to and will continue developing nadofaragene firadonavec as an important treatment option for bladder cancer patients with the goal of commercialization, if approved.